Related references
Note: Only part of the references are listed.C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications
B. S. Fernandes et al.
MOLECULAR PSYCHIATRY (2016)
The neurobiology and treatment of first-episode schizophrenia
R. S. Kahn et al.
MOLECULAR PSYCHIATRY (2015)
The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies
Ragy R. Girgis et al.
BIOLOGICAL PSYCHIATRY (2014)
Immune System Disturbances in Schizophrenia
Szatmar Horvath et al.
BIOLOGICAL PSYCHIATRY (2014)
The association between depressive symptoms, cognitive function, and inflammation in major depression
Jesper Krogh et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Rafael Ribeiro-Santos et al.
CURRENT NEUROPHARMACOLOGY (2014)
The Longitudinal Course of Cognitive Impairment in Schizophrenia: An Examination of Data From Premorbid Through Posttreatment Phases of Illness
Richard S. E. Keefe
JOURNAL OF CLINICAL PSYCHIATRY (2014)
The Early Longitudinal Course of Cognitive Deficits in Schizophrenia
Keith H. Nuechterlein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Complement and blood-brain barrier integrity
Alexander Jacob et al.
MOLECULAR IMMUNOLOGY (2014)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke et al.
NATURE (2014)
Role of C-reactive protein in schizophrenia: An overview
Bisu Singh et al.
PSYCHIATRY RESEARCH (2014)
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Iris E. Sommer et al.
SCHIZOPHRENIA BULLETIN (2014)
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Rachel Upthegrove et al.
SCHIZOPHRENIA RESEARCH (2014)
A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation
Rune A. Kroken et al.
FRONTIERS IN PSYCHIATRY (2014)
Update on Typical and Atypical Antipsychotic Drugs
Herbert Y. Meltzer
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments
Xia Ge et al.
BMC NEUROLOGY (2013)
C-reactive protein and substance use disorders in adolescence and early adulthood: A prospective analysis
E. Jane Costello et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial
E. Johnsen et al.
EUROPEAN PSYCHIATRY (2013)
Serum markers of inflammation and oxidative stress in chronic opium (Taryak) smokers
Ali Ghazavi et al.
IMMUNOLOGY LETTERS (2013)
Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder
Faith Dickerson et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Stephan Ripke et al.
NATURE GENETICS (2013)
Neuroinflammation in schizophrenia especially focused on the role of microglia
Akira Monji et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Schizophrenia Is a Cognitive Illness Time for a Change in Focus
Rene S. Kahn et al.
JAMA PSYCHIATRY (2013)
Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation
M. Ota et al.
ACTA PSYCHIATRICA SCANDINAVICA (2012)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S. Miyamoto et al.
MOLECULAR PSYCHIATRY (2012)
Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
Alice Egerton et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein
Ingrid Dieset et al.
SCHIZOPHRENIA RESEARCH (2012)
The Complement Control-Related Genes CSMD1 and CSMD2 Associate to Schizophrenia
Bjarte Havik et al.
BIOLOGICAL PSYCHIATRY (2011)
Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond
Urs Meyer et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
K. E. Lewandowski et al.
PSYCHOLOGICAL MEDICINE (2011)
Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing
Claudia Bartels et al.
BMC NEUROSCIENCE (2010)
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone
Erik Johnsen et al.
BMC PSYCHIATRY (2010)
Meta-analysis of the acute effects of nicotine and smoking on human performance
Stephen J. Heishman et al.
PSYCHOPHARMACOLOGY (2010)
The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women
Kristine Yaffe et al.
ARCHIVES OF NEUROLOGY (2009)
What Do We Know About Neuropsychological Aspects Of Schizophrenia?
Barton W. Palmer et al.
NEUROPSYCHOLOGY REVIEW (2009)
Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function
Yasuhiro Kaneda et al.
PSYCHIATRY RESEARCH (2009)
Are Psychotic Psychopathology and Neurocognition Orthogonal? A Systematic Review of Their Associations
Maria de Gracia Dominguez et al.
PSYCHOLOGICAL BULLETIN (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
Complement activation and inhibition: a delicate balance
A. P. Sjoberg et al.
TRENDS IN IMMUNOLOGY (2009)
Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents
Jennifer O'Loughlin et al.
NICOTINE & TOBACCO RESEARCH (2008)
Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia
David L. Garver et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2008)
Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity
Paul M. Ridker
NUTRITION REVIEWS (2007)
The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women
Thomas Dietrich et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2007)
How should DSM-V criteria for schizophrenia include cognitive impairment?
Richard S. E. Keefe et al.
SCHIZOPHRENIA BULLETIN (2007)
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
Faith Dickerson et al.
SCHIZOPHRENIA RESEARCH (2007)
C-Reactive protein and the prediction of cardiovascular events among those at intermediate risk - Moving an inflammatory hypothesis toward consensus
Paul M. Ridker
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Role of complement in neurodegeneration and neuroinflammation
Domenico Marco Bonifati et al.
MOLECULAR IMMUNOLOGY (2007)
Does cognition predict community function only in schizophrenia?: A study of schizophrenia patients, bipolar affective disorder patients, and community control subjects
JoAn R. Laes et al.
SCHIZOPHRENIA RESEARCH (2006)
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia - Involvement of nicotinic receptor mechanisms
KA Sacco et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Practice effects and the use of alternate forms in serial neuropsychological testing
LJ Beglinger et al.
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2005)
Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study
P Ohrmann et al.
SCHIZOPHRENIA RESEARCH (2005)
An introduction to latent growth curve modeling
TE Duncan et al.
BEHAVIOR THERAPY (2004)
The metabolic syndrome, inflammation, and risk of cognitive decline
K Yaffe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Inflammatory markers and cognition in well-functioning African-American and white elders
K Yaffe et al.
NEUROLOGY (2003)
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers
J Théberge et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia
CM Wilk et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff?
MF Green et al.
SCHIZOPHRENIA BULLETIN (2000)
Share Paper
